Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Immune System Diseases | 2 |
Infectious Diseases | 2 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Diagnostic radiopharmaceuticals | 3 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Mar 2000 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Jan 2000 |
Target |
Mechanism TAU inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Jul 2024 |
Sponsor / Collaborator |
Start Date24 Jun 2024 |
Sponsor / Collaborator |
Start Date16 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Bulaquine | Malaria More | Approved |
Bulaquine/Chloroquine Phosphate | Malaria More | Approved |
Izaflortaucipir (18F) ( TAU ) | Cognitive Dysfunction More | Phase 3 |
Eclitasertib ( RIPK1 ) | Colitis, Ulcerative More | Phase 2 |
18F-GPI ( GP IIb/IIIa ) | Venous Thrombosis More | Phase 2 |